Nature Communications · 2025 · 15 citations · 50 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyCancer ImmunotherapyMacrophage BiologyTumor Immune MicroenvironmentTumor Microenvironment ModulationTumor-associated AntigensTumor-associated MacrophagesCancer-associated ImmunosuppressionIge-mediated MechanismsIge-mediated ResponsesImmune Cell ActivationImmunosuppressive MicroenvironmentImmunotherapy For Ovarian CancerOvarian Cancer ImmunologyOvarian Macrophages
Ovarian cancer is the most lethal gynaecological cancer and treatment options remain limited. In a recent first-in-class Phase I trial, the monoclonal IgE antibody MOv18, specific for the tumour-associated antigen Folate Receptor-α, was well-tolerated and preliminary anti-tumoural activity observed. Pre-clinical studies identified macrophages as mediators of tumour restriction and pro-inflammatory activation by IgE. However, the mechanisms of IgE-mediated modulation of macrophages and downstream tumour immunity in human cancer remain unclear. Here we study macrophages from patients with epithelial ovarian cancers naive to IgE therapy. High-dimensional flow cytometry and RNA-seq demonstrate immunosuppressive, FcεR-expressing macrophage phenotypes. Ex vivo co-cultures and RNA-seq interaction analyses reveal immunosuppressive associations between patient-derived macrophages and regulatory T (Treg) cells. MOv18 IgE-engaged patient-derived macrophages undergo pro-inflammatory repolarisation ex vivo and display induction of a hyperinflammatory, T cell-stimulatory subset. IgE reverses macrophage-promoted Treg cell induction to increase CD8+ T cell expansion, a signature associated with improved patient prognosis. On-treatment tumours from the MOv18 IgE Phase I trial show evidence of this IgE-driven immune signature, with increased CD68+ and CD3+ cell infiltration. We demonstrate that IgE induces hyperinflammatory repolarised states of patient-derived macrophages to inhibit Treg cell immunosuppression. These processes may collectively promote immune activation in ovarian cancer patients receiving IgE therapy.
50
Michael A. Bookman, Kathleen M. Darcy, Daniel L. Clarke‐Pearson et al. · Journal of Clinical Oncology · 2003 · 613 citations
Medicine, Gynecology, Oncology +17